IP Verse

Inhibitors Of Bruton'S Tyrosine Kinase - EP2529622

The patent EP2529622 was granted to Pharmacyclics on Jan 17, 2018. The application was originally filed on Dec 28, 2006 under application number EP12166302A. The patent is currently recorded with a legal status of "Revoked".

EP2529622

PHARMACYCLICS
Application Number
EP12166302A
Filing Date
Dec 28, 2006
Status
Revoked
May 24, 2019
Grant Date
Jan 17, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 17, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (75) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004013734
DESCRIPTIONUS3598122
DESCRIPTIONUS3598123
DESCRIPTIONUS3710795
DESCRIPTIONUS3731683
DESCRIPTIONUS3742951
DESCRIPTIONUS3814097
DESCRIPTIONUS3921636
DESCRIPTIONUS3972995
DESCRIPTIONUS3993072
DESCRIPTIONUS3993073
DESCRIPTIONUS3996934
DESCRIPTIONUS4031894
DESCRIPTIONUS4060084
DESCRIPTIONUS4069307
DESCRIPTIONUS4077407
DESCRIPTIONUS4151273
DESCRIPTIONUS4201211
DESCRIPTIONUS4229447
DESCRIPTIONUS4230105
DESCRIPTIONUS4292299
DESCRIPTIONUS4292303
DESCRIPTIONUS4327725
DESCRIPTIONUS4343789
DESCRIPTIONUS4476116
DESCRIPTIONUS4596795
DESCRIPTIONUS4624848
DESCRIPTIONUS4755386
DESCRIPTIONUS4871549
DESCRIPTIONUS4968509
DESCRIPTIONUS5011692
DESCRIPTIONUS5017381
DESCRIPTIONUS5033252
DESCRIPTIONUS5052558
DESCRIPTIONUS5116817
DESCRIPTIONUS5229135
DESCRIPTIONUS5260068
DESCRIPTIONUS5260069
DESCRIPTIONUS5281420
DESCRIPTIONUS5323907
DESCRIPTIONUS5336168
DESCRIPTIONUS5340591
DESCRIPTIONUS5456923
DESCRIPTIONUS5461140
DESCRIPTIONUS5508040
DESCRIPTIONUS5516527
DESCRIPTIONUS5567441
DESCRIPTIONUS5622721
DESCRIPTIONUS5665378
DESCRIPTIONUS5686105
DESCRIPTIONUS5700410
DESCRIPTIONUS5700485
DESCRIPTIONUS5723269
DESCRIPTIONUS5739136
DESCRIPTIONUS5837280
DESCRIPTIONUS5837284
DESCRIPTIONUS5840329
DESCRIPTIONUS5858401
DESCRIPTIONUS5869090
DESCRIPTIONUS5977175
DESCRIPTIONUS6083518
DESCRIPTIONUS6326469
DESCRIPTIONUS6391452
DESCRIPTIONUS6465014
DESCRIPTIONUS6667048
DESCRIPTIONUS6923983
DESCRIPTIONUS6929801
DESCRIPTIONUS6932983
DESCRIPTIONUS6946144
DESCRIPTIONUS6960563
DESCRIPTIONWO0119829
OPPOSITIONUS5530012
OPPOSITIONWO0119829
OPPOSITIONWO02076986
SEARCHWO02076986

Non-Patent Literature (NPL) Citations (40) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADVANCED ORGANICE CHEMISTRY, PLENUM, (2000), vol. B-
DESCRIPTION- ARNOLD ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2000), vol. 10, pages 2167 - 2170-
DESCRIPTION- BURCHAT ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2002), vol. 12, pages 1687 - 1690-
DESCRIPTION- C. A. JEFFRIES ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (2003), vol. 278, pages 26258 - 26264-
DESCRIPTION- CAREY; SUNDBERG, ADVANCED ORGANIC CHEMISTRY 4'x ED., PLENUM PRESS, (2000), vol. A, B-
DESCRIPTION- CAREY; SUNDBERG, Advanced Organic Chemistry, PLENUM PRESS, (2000), vol. A, B-
DESCRIPTION- CAREY; SUNDBERG, ADVANCED ORGANIC CHEMISTRY, vol. A-
DESCRIPTION- DEY ET AL., CYTOJOUMAL, (2006), vol. 3, no. 24-
DESCRIPTION- FEDORAK ET AL., AM. J PHYSIOL., (1995), vol. 269, pages G210 - 218-
DESCRIPTION- FIESER; FIESER'S, Reagents for Organic Synthesis, JOHN WILEY AND SONS, (1991), vol. 1-17-
DESCRIPTION- HOCHHAUS ET AL., BIOMED. CHROM., (1992), vol. 6, pages 283 - 286-
DESCRIPTION- IWAKI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (2005), vol. 280, no. 48, pages 40261 - 40270-
DESCRIPTION- J. B. SMAILL ET AL., J MED. CHEM, (1999), vol. 42, no. 10, pages 1803 - 1815-
DESCRIPTION- J. B. SMAILL ET AL., J MED. CHEM., (1999), vol. 42, page 1803-
DESCRIPTION- J. LARSEN ET AL., INT. J PHARMACEUTICS, (1988), vol. 47, page 103-
DESCRIPTION- J. LARSEN; H. BUNDGAARD, INT. J. PHARMACEUTICS, (1987), vol. 37, page 87-
DESCRIPTION- KUROSAKI, CURR OP IMM, (2000), pages 276 - 281-
DESCRIPTION- KUZMIC ET AL., ANAL. BIOCHEM., (2000), vol. 286, pages 45 - 50-
DESCRIPTION- LIBERMAN ET AL., Pharmaceutical Dosage Forms, (1990), vol. 1, pages 209 - 214-
DESCRIPTION- MCLOED ET AL., GASTROENTEROL, (1994), vol. 106, pages 405 - 413-
DESCRIPTION- NANDAKUMAR ET AL., AM. J PATHOL, (2003), vol. 163, pages 1827 - 1837-
DESCRIPTION- NANDAKUMAR ET AL., AM. J. PATHOL., (2003), vol. 163, pages 1827 - 1837-
DESCRIPTION- NISITANI ET AL., PROC. NATL. ACAD. SCI, USA, (1999), vol. 96, pages 2221 - 2226-
DESCRIPTION- N. J. HORWOOD ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, (2003), vol. 197, pages 1603 - 1611-
DESCRIPTION- NOGRADY, Medicinal Chemistry A BiochemicalApproach, OXFORD UNIVERSITY PRESS, (1985), pages 388 - 392-
DESCRIPTION- Organic Reactions, JOHN WILEY AND SONS, (1991), vol. 1-40-
DESCRIPTION- PAGEL ET AL., CLIN CANCER RES, (2005), vol. 11, no. 13, pages 4857 - 4866-
DESCRIPTION- QUEK ET AL., CURRENT BIOLOGY, (1998), vol. 8, no. 20, pages 1137 - 1140-
DESCRIPTION- Rodd's Chemistry of Carbon Compounds, ELSEVIER SCIENCE PUBLISHERS, (1989), vol. 1-5-
DESCRIPTION- SAULNIER ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (1994), vol. 4, page 1985-
DESCRIPTION- SCHAEFFER; SCHWARTZBERG, CURR OP IMM, (2000), pages 282 - 288-
DESCRIPTION- SILVERMAN, The Organic Chemistry of Drug Design and Drug Action, ACADEMIC PRESS, INC., (1992), pages 352 - 401-
DESCRIPTION- SINGH ET AL., Encyclopedia of Pharmaceutical Technology, (2002), pages 751 - 753-
DESCRIPTION- SINGH ET AL., Encyclopedia of Pharmaceutical Technology, (2002), pages 754 - 757-
DESCRIPTION- SINKULA ET AL., J PHARM. SCI., (1975), vol. 64, pages 181 - 210-
DESCRIPTION- T. HIGUCHI; V. STELLA, Prodrugs as Novel Delivery Systems, A.C.S. SYMPOSIUM SERIES, vol. 14-
DESCRIPTION- VASSILEV ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (1999), vol. 274, no. 3, pages 1646 - 1656-
OPPOSITION- CALVO E. et al., "Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study", Clinical Cancer Research, (20040000), vol. 10, pages 7112 - 7120, XP055524879-
OPPOSITION- PAN Z. et al., "Discovery of Selective Irreversible Inhibitors for Brutons Tyrosine Kinase", ChemMedChem., vol. 2, no. 1, (20070000), pages 58 - 61, (20061212), XP008118842
OPPOSITION- MAHAJAN S. et al., "RATIONAL DESIGN AND SYNTHESIS OF A NOVEL ANTI-LEUKEMIC AGENT TARGETING BRUTON'S TYROSINE KINASE (BTK), LFM-A13 ÚALPHA-CYANO-BETA-HYDROXY-BETA-METHYL-N-(2,5-DIBROMOPHENYL)PROPENAMIDE3⁄4", J. Biol. Chem., (19990000), vol. 274, no. 14, pages 9587 - 9599, XP000856755

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents